Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

7.2K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
7.2K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

20.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
20.1K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.2K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained mucosal delivery of SAMT-247 via an intravaginal ring reduces the risk of SIV<sub>mac251</sub> acquisition in vaccinated macaques.

Cell reports. Medicine·2026
Same author

Global Proteomics Investigation of SAMT-247 Targets: An Antiviral Thioester that Acetylates Zinc Finger Proteins.

bioRxiv : the preprint server for biology·2026
Same author

Bioisosteric Replacement of Amides with 1,2,3-Triazoles Improves Dopamine D4 Receptor Ligand Pharmacokinetics.

ACS pharmacology & translational science·2026
Same author

RNA detection on a microfluidic platform using Thyclotides.

Sensors and actuators reports·2025
Same author

Sulfanylbenzamides with Unique Side Chains to Improve Metabolic Stability, Pharmacokinetics, and Anti-HIV Activity.

Journal of medicinal chemistry·2025
Same author

7-Methylguanine With a Cyclopentane Backbone: A Bright Combination for a FIT-PNA RNA Sensor.

British journal of biomedical science·2025

Related Experiment Video

Updated: Apr 14, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

797

PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor.

Andrew V Dix1, Jennie L Conroy1, Kara M George Rosenker1

  • 1Laboratory of Bioorganic Chemistry, NIDDK, and Molecular Neuropharmacology Section, NINDS, National Institutes of Health , Bethesda, Maryland 20892, United States.

ACS Medicinal Chemistry Letters
|April 21, 2015
PubMed
Summary
This summary is machine-generated.

Peptide nucleic acid scaffolds were synthesized to study how multiple ligands binding to dopamine D2 receptors (D2R) affect neurological diseases. This research explores multivalent effects on D2R activity.

Keywords:
Peptide nucleic aciddopamine D2 receptormultivalent displayself-assembly

More Related Videos

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

9.1K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.7K

Related Experiment Videos

Last Updated: Apr 14, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
09:44

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases

Published on: May 2, 2025

797
Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
07:25

Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology

Published on: March 27, 2018

9.1K
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
09:54

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area

Published on: August 10, 2012

26.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Neuroscience

Background:

  • Membrane receptors, such as dopamine D2 receptors (D2R), are crucial in cellular signaling.
  • G-protein coupled receptors (GPCRs) like D2R can form higher-ordered structures implicated in neurological disorders.
  • Understanding multivalent ligand binding is key to receptor pharmacology.

Purpose of the Study:

  • To synthesize and evaluate peptide nucleic acid (PNA) scaffolds modified with a D2R agonist.
  • To investigate the multivalent effects of ligand binding on D2R activity.
  • To explore potential therapeutic strategies for D2R-associated neurological diseases.

Main Methods:

  • Synthesis of a library of ligand-modified PNA constructs.
  • Incorporation of the D2R agonist (±)-PPHT onto PNA scaffolds.
  • Assessment of D2R activity for each synthesized construct.

Main Results:

  • Successful synthesis of a diverse PNA scaffold library.
  • Demonstration of varying D2R activity across different PNA constructs.
  • Initial evaluation of multivalent binding effects on receptor activity.

Conclusions:

  • PNA scaffolds offer a versatile platform for studying receptor-ligand interactions.
  • Multivalent binding significantly influences dopamine D2 receptor activity.
  • This approach provides insights into GPCRs and potential therapeutic interventions for neurological conditions.